(18)F-fluorodeoxyglucose and (18)F-flumazenil positron emission tomography in patients with refractory epilepsy.
BACKGROUND
Epilepsy is a neurological disorder characterized by epileptic seizures as a result of excessive neuronal activity in the brain. Approximately 65 million people worldwide suffer from epilepsy; 20-40% of them are refractory to medication therapy. Early detection of disease is crucial in the management of patients with epilepsy. Correct localization of the ictal onset zone is associated with a better surgical outcome. The modern non-invasive techniques used for structural-functional localization of the seizure focus includes electroencephalography (EEG) monitoring, magnetic resonance imaging (MRI), single photon emission tomography/computed tomography (SPECT/CT) and positron emission tomography/computed tomography (PET/CT). PET/CT can predict surgical outcome in patients with refractory epilepsy. The aim of the article is to review the current role of routinely used tracer 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) as well as non routinely used (18)F-Flumazenil ((18)F-FMZ) tracers PET/CT in patients with refractory epilepsy.


CONCLUSIONS
Functional information delivered by PET and the morphologic information delivered by CT or MRI are essential in presurgical evaluation of epilepsy. Nowadays (18)F-FDG PET/CT is a routinely performed imaging modality in localization of the ictal onset zone in patients with refractory epilepsy who are unresponsive to medication therapy. Unfortunately, (18)F-FDG is not an ideal PET tracer regarding the management of patients with epilepsy: areas of glucose hypometabolism do not correlate precisely with the proven degree of change within hippocampal sclerosis, as observed by histopathology or MRI. Benzodiazepine-receptor imaging is a promising alternative in nuclear medicine imaging of epileptogenic focus. The use of (11)C-FMZ in clinical practice has been limited by its short half-life and necessitating an on-site cyclotron for production. Therefore, (18)F-FMZ might be established as one of the tracers of choice for patients with refractory epilepsy because of better sensitivity and anatomical resolution.
Nuclear Medicine Research Department, Iason, Graz, Austria; Department of Nuclear Medicine, Palacký University Olomouc, Czech Republic.
Marina
M
Hodolic
Department of Neurology, Klinikum Wels-Grieskirchen, Wels, Austria.
Raffi
R
Topakian
Institute of Nuclear Medicine, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.
Robert
R
Pichler
18F-FDG; 18F-Flumazenil; PET/CT; epilepsy; nuclear medicine
Mol Imaging Biol. 2002 Oct;4(5):338-51
14537108
Eur J Pharmacol. 1985 Apr 2;110(2):247-51
2985411
PET Clin. 2014 Jul;9(3):267-76
25030390
Epilepsy Res. 2013 Aug;105(3):356-61
23582605
N Engl J Med. 2000 Feb 3;342(5):314-9
10660394
Ann Indian Acad Neurol. 2013 Oct;16(4):676-7
24339606
Eur J Nucl Med. 2001 Oct;28(10):1463-70
11685488
Epilepsia. 1998 Jun;39(6):651-9
9637608
Arch Neurol. 1995 Mar;52(3):314-7
7872887
Epilepsia. 1992 Jul-Aug;33(4):624-34
1628575
Ann Neurol. 1992 Dec;32(6):789-94
1471870
Epilepsia. 2014 Jun;55(6):878-85
24701994
Neuroradiology. 1997 Nov;39(11):788-96
9406205
Nihon Rinsho. 2014 May;72(5):827-33
24912282
Nucl Med Biol. 2004 Feb;31(2):291-5
15013496
Neuroimage. 2002 Sep;17(1):302-16
12482085
N Engl J Med. 2001 Aug 2;345(5):311-8
11484687
J Neurol Neurosurg Psychiatry. 1993 Jun;56(6):615-21
8509773
Epilepsia. 1994;35 Suppl 6:S72-89
8206016
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2103-10
19838705
Lancet Neurol. 2014 Nov;13(11):1114-1126
25316018
J Nucl Med. 1995 Jul;36(7):1141-9
7790936
Ann Neurol. 1982 Dec;12(6):529-37
6818897
Epileptic Disord. 2015 Jun;17(2):177-83
25906169
Ann Neurol. 1980 Oct;8(4):348-60
6776878
Epilepsy Res. 2014 Oct;108(8):1306-14
25043753
Nucl Med Biol. 2005 Apr;32(3):263-8
15820761
JAMA. 2015 Apr 21;313(15):1572
25898058
Epilepsia. 2011 Sep;52 Suppl 7:2-26
21899536
Eur J Pharmacol. 1992 Jul 21;218(1):109-15
1327820
J Psychiatry Neurosci. 1994 Jan;19(1):24-9
8148363
Neurology. 1996 Oct;47(4):1015-20
8857738
J Nucl Med. 1998 Feb;39(2):285-93
9476937
Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):416-30
26550535
AJNR Am J Neuroradiol. 2001 May;22(5):937-46
11337340
Int Rev Cytol. 2002;213:1-47
11837891
J Neurochem. 2004 Mar;88(6):1431-8
15009644
Ann Neurol. 1982 Dec;12(6):518-28
6984318
J Nucl Med. 2013 Aug;54(8):1270-7
23857513
Lancet. 1988 Oct 15;2(8616):863-6
2902315
J Neurosci. 1992 Mar;12(3):924-9
1372045
AJNR Am J Neuroradiol. 1999 Apr;20(4):593-9
10319968
Psychiatry Res. 1993 Apr;50(1):1-13
8390063
Medicine (Baltimore). 2015 Feb;94(6):e500
25674741
Int J Appl Radiat Isot. 1984 Oct;35(10):973-6
6094361
Neurology. 2003 Feb 25;60(4):538-47
12601090
Nucl Med Biol. 2001 Oct;28(7):809-14
11578902
Brain. 2012 Sep;135(Pt 9):2817-25
22961552
Nucl Med Commun. 2001 Feb;22(2):233-7
11258411
Seizure. 2007 Sep;16(6):509-20
17532231
Epilepsia. 2000 Dec;41(12):1560-6
11114214
Epilepsia. 2013 Feb;54(2):341-50
23030361
Stroke. 2000 Feb;31(2):366-9
10657407
Epilepsy Res Treat. 2011;2011:303624
22937231
J Nucl Med. 1990 Jun;31(6):1007-14
2161451
Neurology. 1994 Dec;44(12):2331-6
7991121
J Neurol Sci. 1996 Apr;137(1):28-34
9120484
Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):579-88
17938922
Nucl Med Biol. 2005 Feb;32(2):109-16
15721755
J Nucl Med. 1999 May;40(5):737-46
10319744